|
**Overview**: Amenorrhea Andrology Screen Panel**Introduction**: The Amenorrhea Andrology Screen Panel is a diagnostic tool designed to screen for causes of amenorrhea using serum samples. In India, amenorrhea affects a significant number of women of reproductive age, with prevalence estimates of 3-5 percent for secondary amenorrhea and higher in certain communities due to PCOS (polycystic ovary syndrome, affecting 20-30 percent of women in some urban studies), nutritional deficiencies, stress, thyroid disorders, and hyperprolactinemia. Common presentations include absence of menstruation, infertility, hirsutism, weight gain, or galactorrhea. High morbidity from underdiagnosis in rural/low-SES women, limited endocrinology access, cultural stigma, and delayed treatment leading to infertility or metabolic complications. Per endocrinology and biochemistry practices aligned with ICMR and Indian Society of Endocrinology guidelines, the test employs spectrophotometry and immunoassay for detailed parameter analysis (LH, FSH, prolactin) over 1-2 days with high sensitivity/specificity, valuable for initial hormonal evaluation in amenorrhea cases. This diagnostic falls under hormonal disorder screening and targets women with amenorrhea, addressing accurate detection to guide further investigation and management. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment (e.g., ovulation induction, prolactin control), and reducing long-term complications like osteoporosis or infertility. Its serum-based approach ensures reliable performance in India's diverse lab settings.**Other Names**: Amen Andro Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/biochemistry, compliant with 2025 standards.**Historical Milestone**: Developed for hormonal screening; in India, prominence with rising PCOS and infertility awareness.**Purpose**: The test screens for 3 parameters including LH and FSH to guide amenorrhea assessment, evaluate hormonal causes, inform further endocrine evaluation.**Test Parameters**: 1. LH, 2. FSH, 3. Prolactin.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report menstrual irregularities, weight changes, hirsutism, galactorrhea, or infertility.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on menstrual history, weight changes, hirsutism, galactorrhea, stress, medications, family history of endocrine disorders.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated amenorrhea including infertility or metabolic issues, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry and immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent stress/medications can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hormonal causes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Gynecologists or endocrinologists should be consulted for case management, treatment planning, and coordination with reproductive health programs.**Additional Supporting Tests**: Thyroid function tests, pelvic ultrasound, or progesterone challenge for confirmation.**Test Limitations**: The test may miss non-hormonal causes or require cycle timing; comprehensive approach with clinical correlation required.**References**: Indian Journal of Endocrinology 2024, PCOS and Amenorrhea Studies India 2023. |
